176 related articles for article (PubMed ID: 33300112)
21. Prevalence and significance of HMGA2 expression in oesophageal adenocarcinoma.
Mito JK; Agoston AT; Dal Cin P; Srivastava A
Histopathology; 2017 Dec; 71(6):909-917. PubMed ID: 28710822
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
[TBL] [Abstract][Full Text] [Related]
23. Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma.
Obulkasim A; Ylstra B; van Essen HF; Benner C; Stenning S; Langley R; Allum W; Cunningham D; Inam I; Hewitt LC; West NP; Meijer GA; van de Wiel MA; Grabsch HI
Oncotarget; 2016 Jul; 7(28):44084-44095. PubMed ID: 27286451
[TBL] [Abstract][Full Text] [Related]
24. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
[TBL] [Abstract][Full Text] [Related]
25. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
26. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
27. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
29. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Miller CT; Moy JR; Lin L; Schipper M; Normolle D; Brenner DE; Iannettoni MD; Orringer MB; Beer DG
Clin Cancer Res; 2003 Oct; 9(13):4819-25. PubMed ID: 14581353
[TBL] [Abstract][Full Text] [Related]
30. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
[TBL] [Abstract][Full Text] [Related]
31. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements: a retrospective multicenter study.
Taniyama Y; Murakami K; Yoshida N; Takahashi K; Matsubara H; Baba H; Kamei T
BMC Cancer; 2021 Sep; 21(1):1008. PubMed ID: 34496769
[TBL] [Abstract][Full Text] [Related]
33. Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients.
Buck A; Prade VM; Kunzke T; Feuchtinger A; Kröll D; Feith M; Dislich B; Balluff B; Langer R; Walch A
J Pathol; 2022 Feb; 256(2):202-213. PubMed ID: 34719782
[TBL] [Abstract][Full Text] [Related]
34. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
35. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
36. The roles of neoadjuvant radiotherapy and lymphadenectomy in the treatment of esophageal adenocarcinoma.
Solomon N; Zhuge Y; Cheung M; Franceschi D; Koniaris LG
Ann Surg Oncol; 2010 Mar; 17(3):791-803. PubMed ID: 19953332
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference.
Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J
Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052
[TBL] [Abstract][Full Text] [Related]
38. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
39. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]